SYS-CON MEDIA Authors: Jayaram Krishnaswamy, Lori MacVittie, Gilad Parann-Nissany, Unitiv Blog, Bob Gourley

News Feed Item

Clinical Trial Results, Partnerships, and Reimbursement Rates - Research Report on Celldex, Centene, Enanta, Novartis, and BG Medicine

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 13, 2013 /PRNewswire/ --


Today, Analysts' Corner announced new research reports highlighting Celldex Therapeutics, Inc. (NASDAQ: CLDX), Centene Corp. (NYSE: CNC), Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), Novartis AG (NYSE: NVS), and BG Medicine, Inc. (NASDAQ: BGMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On December 10, 2013, Celldex Therapeutics, Inc. (Celldex) announced positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil (Plerixafor injection, formerly AMD3100). According to the Company, the study demonstrates that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The Company also informed that the data support future clinical development of CDX-301 and demonstrate a novel potent cell mobilization regimen combining CDX-301 and Mozobil®, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. "The data presented today further demonstrate the potential for CDX-301 to improve both autologous and allogeneic hematopoietic stem cell transplantation and, importantly, show the ability for CDX-301 to combine effectively with other cell mobilization agents," said Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer at Celldex. "If what has been demonstrated in preclinical models can be applied to a clinical setting, this regimen could improve stem cell transplantation outcomes for patients across a broad range of indications. We plan to initiate a pilot clinical study evaluating CDX-301 alone and in combination with Mozobil® in the transplant setting in early 2014 and look forward to seeing how this program progresses." The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/b443_CLDX

--

Centene Corp. Research Report

On December 10, 2013, Centene Corp. (Centene) announced that its wholly-owned behavioral health subsidiary Cenpatico of Arizona is entering into a strategic alliance with the University of Arizona Health Network, seeking opportunities to deliver an innovative and highly effective model for whole person healthcare in Arizona. "Both Centene and UAHN bring together their years of experience in managing these vulnerable populations, and we look forward to participating in the state's procurement in 2014, in which we will articulate the vision for integrated healthcare," said Jason M. Harrold, Executive Vice President of Specialty Business at Centene. The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/e85d_CNC

--

Enanta Pharmaceuticals, Inc. Research Report

On December 10, 2013, Enanta Pharmaceuticals, Inc. (Enanta) announced results from the SAPPHIRE-II study, conducted by AbbVie for the treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection, using a regimen containing the Company's lead protease inhibitor ABT-450. According to the Company, results from the SAPPHIRE-II trial demonstrated a sustained virologic response at 12 weeks post-treatment of 96% in chronically infected GT1 HCV treatment experienced adult patients who had previously failed pegylated interferon and ribavirin treatment. "The high SVR rates in this SAPPHIRE-II trial and the previously reported SAPPHIRE-I trial further validate this 3D regimen plus ribavirin for both treatment-naive and treatment-experienced patients," said Jay R. Luly, Ph.D., President and CEO of Enanta. "We look forward to the remaining phase 3 studies reading out using the same 3D regimen with and without ribavirin, as well as in the treatment of HCV patients with cirrhosis." The Full Research Report on Enanta Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/a066_ENTA

--

Novartis AG Research Report

On December 6, 2013, Novartis AG (Novartis) announced results of a Phase III trial of the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone. According to the Company, the study met the primary endpoint of significantly extending progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone. Novartis informed that LBH589 showed significant clinical benefit bringing it a step closer to becoming the first in its class of anticancer agents to be available to patients with multiple myeloma. "Results from this study show improved outcomes for these multiple myeloma patients who otherwise have few options to treat this incurable disease," said Alessandro Riva, Global Head, Oncology Development and Medical Affairs, Novartis Oncology. "Given its mechanism of action, LBH589 has the potential to be an important treatment option for multiple myeloma." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/9b6d_NVS

--

BG Medicine, Inc. Research Report

On December 10, 2013, BG Medicine Inc. (BG Medicine) announced that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test at the amount of a crosswalked test, whose 2014 national limitation amount is $30.01. The Company stated that the national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013. "We are very pleased that CMS has finalized the previously announced preliminary determination of the Medicare reimbursement rate for our galectin-3 test," said Dr. Paul R. Sohmer, President and CEO of BG Medicine. The Full Research Report on BG Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/e181_BGMD

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

  1. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  2. For any urgent concerns or inquiries, please contact us at [email protected].
  3. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.